Marksans Pharma Limited (BOM:524404)
187.90
-2.15 (-1.13%)
At close: Dec 4, 2025
Marksans Pharma Revenue
Marksans Pharma had revenue of 7.20B INR in the quarter ending September 30, 2025, with 12.23% growth. This brings the company's revenue in the last twelve months to 27.31B, up 14.80% year-over-year. In the fiscal year ending March 31, 2025, Marksans Pharma had annual revenue of 26.23B with 20.46% growth.
Revenue (ttm)
27.31B
Revenue Growth
+14.80%
P/S Ratio
3.05
Revenue / Employee
14.84M
Employees
1,840
Market Cap
83.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
Marksans Pharma News
- 18 days ago - Marksans Pharma gets final USFDA approval for Loperamide Hydrochloride Tablets - Business Upturn
- 19 days ago - Marksans Pharma Ltd (BOM:524404) Q2 2026 Earnings Call Highlights: Strong US Growth and ... - GuruFocus
- 19 days ago - Q2 2026 Marksans Pharma Ltd Earnings Call Transcript - GuruFocus
- 20 days ago - Marksans Pharma secures UK MHRA approval for 250 mg and 500 mg Mefenamic Acid - Business Upturn
- 27 days ago - Marksans Pharma’s Goa facility clears US FDA inspection with zero observations - Business Upturn
- 4 weeks ago - Marksans Pharma shares rise after UK MHRA approval for cancer drug Exemestane 25mg tablets - Business Upturn
- 4 weeks ago - Marksans Pharma’s UK subsidiary Relonchem gets MHRA approval for Exemestane 25mg Tablets - Business Upturn
- 7 weeks ago - Marksans Pharma’s UK subsidiary Relonchem secures MHRA approval for two products - Business Upturn